Exelixis
EXEL
#1765
Rank
C$16.46 B
Marketcap
C$61.16
Share price
0.05%
Change (1 day)
20.20%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

P/E ratio for Exelixis (EXEL)

P/E ratio as of January 2026 (TTM): 18.5

According to Exelixis's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 18.5126. At the end of 2023 the company had a P/E ratio of 36.7.

P/E ratio history for Exelixis from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202336.730.49%
202228.113.92%
202124.7-54.46%
202054.2226.32%
201916.694.37%
20188.55-85.09%
201757.4-226.95%
2016-45.2540.88%
2015-7.05580.52%
2014-1.04-77.69%
2013-4.64

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
GlaxoSmithKline
GSK
14.0-24.31%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
12.8-30.61%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
14.4-22.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
18.8 1.43%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
25.0 34.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
20.1 8.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
14.7-20.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
-0.2493-101.35%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-17.9-196.46%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.